A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 15 Sep 2018
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; Ganitumab (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 31 May 2018 Status changed from completed to discontinued.
- 18 Jul 2017 Status changed from active, no longer recruiting to completed.